More NIH Closed Meetings Set for Research Grant Application Reviews
Published Date: 3/25/2026
Notice
Summary
The Center for Scientific Review is holding several closed virtual meetings in April 2026 to review and evaluate important grant applications. These meetings protect private info and trade secrets while deciding who gets research funding. Scientists and researchers applying for grants should note the dates and prepare for decisions that could impact their projects and funding.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
NIH Closed Grant Review Meetings
The NIH Center for Scientific Review will hold multiple closed virtual meetings on April 20, 2026 and April 21–22, 2026 to review and evaluate grant applications. The meetings are closed under sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., to protect confidential trade secrets and personal information. Scientists and researchers applying for NIH grants should note these dates because funding decisions for submitted applications will be reviewed on those days.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14966, Government-Owned Inventions; Availability for Licensing
The National Institutes of Health is offering a new Ebola vaccine invention for companies to license and develop quickly. This vaccine targets the Bundibugyo virus and promises fast and lasting protection, helping stop outbreaks in Central Africa. Businesses interested in licensing should act soon to bring this life-saving tech to market and can contact NIH for details.
Previous / Next Documents
Previous: 2026-05826, Center for Scientific Review; Amended Notice of Meeting
The NIH’s Center for Scientific Review updated a meeting notice for their Training and Career Development (K Awards) panel, changing the panel’s name and confirming the meeting is closed to the public. This affects researchers applying for K Awards and keeps the same April 9-10, 2026 schedule in Bethesda, MD. No money changes, just a clearer name and official update to keep everyone in the loop!
Next: 2026-05828, National Cancer Institute; Notice of Meeting
The National Cancer Institute is holding a virtual public meeting on April 8, 2026, to review new research ideas and programs. Anyone interested in cancer research or policy can join online or send in comments before the meeting. This is a great chance for researchers, advocates, and the public to help shape future cancer studies and funding decisions.